News

Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Oct 20, 2020

Neurology Live

DaxibotulinumtoxinA Meets Primary End Point in Cervical Dystonia Study Learn More

Aug 26, 2020

Modern Aesthetics

Revance Commercial Infrastructure to Roll Out RHA Collection of Dermal Fillers Learn More

Aug 25, 2020

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers Learn More

Jul 29, 2020

Dustin S. Sjuts of Revance Therapeutics: Five Things You Need To Know To Succeed In The Modern Beauty Industry Learn More

Jul 27, 2020

Neurology Live

DaxibotulinumtoxinA Aims to Be Next Big Post-Stroke Spasticity Treatment Learn More

Jul 23, 2020

Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices Learn More

Jun 30, 2020

Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection Learn More

Jun 30, 2020

Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively Learn More

Jun 1, 2020

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX® Learn More

May 19, 2020

Revance announces addition of fintech platform for aesthetic practices with acquisition of HintMD Learn More

Feb 6, 2020

Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines Learn More

Job Opportunities

Do you have what it takes to join our team? Check out our Careers page and find out.

Search Jobs

Latest News:

Job Opportunities

Aesthetics

Therapeutics

Investors

Company

Careers